Concordance Between ER, PR, HER2 neu Receptors Before and After Neoadjuvant Chemotherapy in Locally Advanced Breast Cancer

Taha Heba F.; Elfarargy Ola M.; Salem Reham A.; Mandour Doaa; Salem Amira A.; Riad Mohamed

doi:10.2478/fco-2019-0021

Forum of Clinical Oncology (May 2021)

Concordance Between ER, PR, HER2 neu Receptors Before and After Neoadjuvant Chemotherapy in Locally Advanced Breast Cancer

Taha Heba F.,
Elfarargy Ola M.,
Salem Reham A.,
Mandour Doaa,
Salem Amira A.,
Riad Mohamed

Affiliations

Taha Heba F.: Medical Oncology Department, Faculty of Medicine, Zagazig University, Zagazig, Egypt
Elfarargy Ola M.: Medical Oncology Department, Faculty of Medicine, Zagazig University, Zagazig, Egypt
Salem Reham A.: Clinical Oncology and Nuclear Medicine Department, Faculty of Medicine, Zagazig University, Zagazig, Egypt
Mandour Doaa: Clinical Oncology and Nuclear Medicine Department, Faculty of Medicine, Zagazig University, Zagazig, Egypt
Salem Amira A.: Pathology Department, Faculty of Medicine, Zagazig University, Zagazig, Egypt
Riad Mohamed: General Surgery Department, Faculty of Medicine, Zagazig University, Zagazig, Egypt

DOI: https://doi.org/10.2478/fco-2019-0021
Journal volume & issue: Vol. 12, no. 1
pp. 3 – 11

Abstract

Read online

Introducing neoadjuvant chemotherapy (NCT) in a breast cancer patient may be associated with changes in estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth hormone receptor 2 (HER2) status.

Published in Forum of Clinical Oncology

ISSN: 1792-362X (Online)
Publisher: Sciendo
Country of publisher: Poland
LCC subjects: Medicine: Internal medicine: Neoplasms. Tumors. Oncology. Including cancer and carcinogens
Website: https://sciendo.com/journal/FCO

About the journal

Abstract

Keywords